Table 2 Correlation between various CTC phenotypes counts and clinicopathological characteristics.
Characteristic | Total CTC (x ± s) | p-value | CSV-CTC (x ± s) | p-Value | Panck-CTC (x ± s) | p-value | Mixed-CTC (x ± s) | p-value | |
|---|---|---|---|---|---|---|---|---|---|
Age | < 60 | 3.9 ± 2.6 | 0.73 | 2.1 ± 1.7 | 0.48 | 0.7 ± 0.8 | 0.50 | 1.0 ± 0.8 | 0.33 |
≥ 60 | 3.6 ± 2.5 | 2.5 ± 1.9 | 0.6 ± 0.6 | 0.8 ± 0.7 | |||||
Gender | Male | 4.3 ± 2.6 | 0.22 | 2.6 ± 1.9 | 0.23 | 0.8 ± 0.7 | 0.28 | 0.8 ± 0.6 | 0.86 |
Female | 3.6 ± 2.4 | 2.1 ± 1.8 | 0.6 ± 0.6 | 0.9 ± 0.8 | |||||
T-stage | T1-2 | 1.3 ± 2.3 | 0.07 | 0.7 ± 1.2 | 0.11 | 0.3 ± 0.6 | 0.36 | 0.3 ± 0.6 | 0.20 |
T3-4 | 4.0 ± 2.5 | 2.4 ± 1.8 | 0.7 ± 0.7 | 0.9 ± 0.7 | |||||
N-stage | N1 | 3.4 ± 2.6 | 0.14 | 2.0 ± 1.9 | 0.12 | 0.6 ± 0.6 | 0.28 | 0.8 ± 0.7 | 0.50 |
N2 | 4.2 ± 2.4 | 2.6 ± 1.8 | 0.7 ± 0.7 | 0.9 ± 0.7 | |||||
M-stage | M0 | 3.3 ± 2.4 | < 0.01* | 1.9 ± 1.8 | < 0.01* | 0.6 ± 0.6 | 0.02* | 0.8 ± 0.7 | 0.06 |
M1a | 5.3 ± 2.2 | 3.4 ± 1.5 | 0.9 ± 0.7 | 1.1 ± 0.8 | |||||
CEA level | normal | 3.6 ± 2.3 | 0.40 | 2.3 ± 1.7 | 0.65 | 0.6 ± 0.7 | 0.47 | 0.7 ± 0.7 | 0.18 |
Abnormal | 4.1 ± 2.7 | 2.4 ± 2.0 | 0.7 ± 0.6 | 1.0 ± 0.7 | |||||
Tumor location | Right | 5.4 ± 2.3 | < 0.01* | 3.5 ± 1.9 | < 0.01* | 0.9 ± 0.6 | 0.08 | 1.1 ± 0.7 | 0.10 |
Left | 3.2 ± 2.3 | 1.8 ± 1.6 | 0.7 ± 0.6 | 0.8 ± 0.7 | |||||
BRAF gene status | Wild | 3.9 ± 2.4 | 0.77 | 2.3 ± 1.7 | 0.87 | 0.7 ± 0.7 | 0.86 | 0.9 ± 0.7 | 0.98 |
Mutation | 4.1 ± 3.1 | 2.4 ± 2.3 | 0.6 ± 0.6 | 0.9 ± 0.7 | |||||
RAS gene status | Wild | 3.4 ± 2.4 | 0.03* | 2.0 ± 1.8 | 0.03* | 0.6 ± 0.6 | 0.38 | 0.8 ± 0.7 | 0.24 |
Mutation | 4.6 ± 2.6 | 2.9 ± 1.7 | 0.8 ± 0.7 | 1.0 ± 0.7 |
